共 53 条
[1]
Hanahan D.(2000)The hallmarks of cancer Cell 100 57-70
[2]
Weinberg R.A.(2002)Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors J Med Chem 45 1300-12
[3]
Hennequin L.F.(2002)ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645-55
[4]
Stokes E.S.(2003)Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546-56
[5]
Thomas A.P.(2002)ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 7284-90
[6]
Wedge S.R.(2004)Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells Cancer Res 64 3823-9
[7]
Ogilvie D.J.(2009)Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions Oncologist 14 378-90
[8]
Dukes M.(2007)Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 4270-7
[9]
Ciardiello F.(2008)Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 26 5407-15
[10]
Caputo R.(2009)Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study J Clin Oncol 27 2523-9